Sanofi (SNY) Research & Development (2009 - 2026)
Sanofi (SNY) posted Research & Development of -$2.6 billion for Q2 2026, down 26.9% sequentially from -$2.0 billion in Q1 2026, and down 20.11% YoY from -$3.2 billion in Q2 2025.
Sanofi (SNY) Research & Development (2009 - 2026) Analysis & Trends
Sanofi has reported Research & Development for 18 years, with the latest figure at -$2.6 billion in Q2 2026.
- Quarterly Research & Development fell 20.11% year-over-year to -$2.6 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$20.3 billion (down 45.3% YoY) and the FY2025 annual result came in at $9.1 billion, up 15.53% from the prior year.
- Research & Development fell to -$2.6 billion in Q2 2026 per SNY's latest filing, from -$2.0 billion in the prior quarter.
- Over five years, Research & Development peaked at -$1.7 billion in Q1 2022 and troughed at -$9.1 billion in Q4 2025.
- A 5-year average of -$3.3 billion and a median of -$1.9 billion in 2024 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2025: Research & Development retreated 0.33% in 2023, then tumbled 227.92% in 2025.
- Over 5 years, Research & Development stood at -$5.0 billion in 2022, then sank by 40.53% to -$7.0 billion in 2023, then slipped by 12.86% to -$7.9 billion in 2024, then declined by 15.53% to -$9.1 billion in 2025, then soared by 71.57% to -$2.6 billion in 2026.
- According to Business Quant data, Research & Development over the past three periods registered -$2.6 billion, -$2.0 billion, and -$9.1 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 2.85 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 4.05 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -4.65 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | -2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.60 Bn |
| Mar 31, 2026 | -2.05 Bn |
| Dec 31, 2025 | -9.13 Bn |
| Sep 30, 2025 | -6.49 Bn |
| Jun 30, 2025 | -2.16 Bn |
| Mar 31, 2025 | -1.90 Bn |
| Dec 31, 2024 | -7.90 Bn |
| Sep 30, 2024 | -1.98 Bn |
| Jun 30, 2024 | -1.79 Bn |
| Mar 31, 2024 | -1.81 Bn |
| Dec 31, 2023 | -7.00 Bn |
| Sep 30, 2023 | -1.81 Bn |
| Jun 30, 2023 | -1.77 Bn |
| Mar 31, 2023 | -1.68 Bn |
| Dec 31, 2022 | -4.98 Bn |
| Sep 30, 2022 | -1.75 Bn |
| Jun 30, 2022 | -1.77 Bn |
| Mar 31, 2022 | -1.67 Bn |
| Dec 31, 2021 | -4.70 Bn |
| Sep 30, 2021 | -1.70 Bn |